Last reviewed · How we verify
Levodopa dispersible
Levodopa is converted to dopamine in the brain, replenishing dopamine levels depleted in Parkinson's disease.
Levodopa is converted to dopamine in the brain, replenishing dopamine levels depleted in Parkinson's disease. Used for Parkinson's disease (motor symptoms).
At a glance
| Generic name | Levodopa dispersible |
|---|---|
| Also known as | Madopar dispersible |
| Sponsor | Seoul National University Hospital |
| Drug class | Dopamine precursor / Antiparkinson agent |
| Target | Dopamine (via conversion by aromatic amino acid decarboxylase) |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
Levodopa (L-DOPA) is a precursor amino acid that crosses the blood-brain barrier and is enzymatically converted to dopamine by aromatic amino acid decarboxylase. This restores dopamine neurotransmission in the basal ganglia, alleviating motor symptoms of Parkinson's disease. The dispersible formulation allows faster absorption and onset of action compared to standard tablets.
Approved indications
- Parkinson's disease (motor symptoms)
Common side effects
- Nausea
- Dyskinesia
- Orthostatic hypotension
- Dizziness
- Hallucinations
- Insomnia
Key clinical trials
- Efficacy of Levodopa/Benserazide Dispersible Tablet on Response Fluctuations in PD Patients With Delayed ON (PHASE4)
- Mucuna Pruriens Therapy in Parkinson's Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Levodopa dispersible CI brief — competitive landscape report
- Levodopa dispersible updates RSS · CI watch RSS
- Seoul National University Hospital portfolio CI